Literature DB >> 3711930

The association of cardiac muscle necrosis and inflammation with the degenerative and persistent myopathy of MDX mice.

L R Bridges.   

Abstract

Two groups of "mdx" mice, totalling 36 animals of both sexes aged between 8 and 30 weeks, have been studied. In the first group of 10 males and 10 females, 8 males (at 8, 12, 20 and 30 weeks) and 4 females (at 12 and 30 weeks) showed severe limb muscle degeneration and inflammation with prominent regeneration and central nucleation of myofibres; fibrosis and fatty infiltration were not a feature. Five males (at 8, 20 and 30 weeks) and 2 females (at 30 weeks) also showed myocardial necrosis and inflammation. In the second group of 8 males and 8 females only 1 mouse, female at 25 weeks, showed similar changes including the myocardial lesion. Three females showed only focal myopathic changes. All the remaining animals in both groups were normal. These findings in terms of the severity and persistence of the myopathy and the myocardial lesion, not hitherto noted in mdx, suggest that it may be of value as an animal model of Duchenne muscular dystrophy (DMD) and/or other human muscle diseases. The variability probably reflects a failure to preserve an homozygous strain.

Entities:  

Mesh:

Year:  1986        PMID: 3711930     DOI: 10.1016/0022-510x(86)90003-1

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  37 in total

1.  Muscular dystrophy: from gene to patient.

Authors:  J C Hopkins; B L Bia; J G Crilley; E A Boehm; A E Sang; J M Tinsley; L M King; G K Radda; K E Davies; K Clarke
Journal:  MAGMA       Date:  2000-11       Impact factor: 2.310

2.  A morphometric technique for the histological quantification of skeletal muscle regeneration.

Authors:  S A Marlow; J K McGeachie; M Tennant; J M Papadimitriou
Journal:  J Anat       Date:  1996-08       Impact factor: 2.610

3.  Recovery of induced mutations for X chromosome-linked muscular dystrophy in mice.

Authors:  V M Chapman; D R Miller; D Armstrong; C T Caskey
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

Review 4.  What do mouse models of muscular dystrophy tell us about the DAPC and its components?

Authors:  Charlotte Whitmore; Jennifer Morgan
Journal:  Int J Exp Pathol       Date:  2014-09-30       Impact factor: 1.925

5.  Freeze-fracture studies of myofiber plasma membrane in X chromosome-linked muscular dystrophy (mdx) mice.

Authors:  S Shibuya; Y Wakayama
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

6.  Deletion of Galgt2 (B4Galnt2) reduces muscle growth in response to acute injury and increases muscle inflammation and pathology in dystrophin-deficient mice.

Authors:  Rui Xu; Neha Singhal; Yelda Serinagaoglu; Kumaran Chandrasekharan; Mandar Joshi; John A Bauer; Paulus M L Janssen; Paul T Martin
Journal:  Am J Pathol       Date:  2015-10       Impact factor: 4.307

7.  Development of Duchenne-type cardiomyopathy. Morphologic studies in a canine model.

Authors:  B A Valentine; J F Cummings; B J Cooper
Journal:  Am J Pathol       Date:  1989-10       Impact factor: 4.307

8.  Adeno-associated virus serotype-9 microdystrophin gene therapy ameliorates electrocardiographic abnormalities in mdx mice.

Authors:  Brian Bostick; Yongping Yue; Yi Lai; Chun Long; Dejia Li; Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2008-08       Impact factor: 5.695

9.  Proteomic Profiling of the Dystrophin-Deficient MDX Heart Reveals Drastically Altered Levels of Key Metabolic and Contractile Proteins.

Authors:  Caroline Lewis; Harald Jockusch; Kay Ohlendieck
Journal:  J Biomed Biotechnol       Date:  2010-05-23

10.  Injection of vessel-derived stem cells prevents dilated cardiomyopathy and promotes angiogenesis and endogenous cardiac stem cell proliferation in mdx/utrn-/- but not aged mdx mouse models for duchenne muscular dystrophy.

Authors:  Ju Lan Chun; Robert O'Brien; Min Ho Song; Blake F Wondrasch; Suzanne E Berry
Journal:  Stem Cells Transl Med       Date:  2012-12-27       Impact factor: 6.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.